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Introduction: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). During the
clinical development programme, increases in mean serum creatinine (SCr) of approximately 0.07 mg/dL and
0.08 mg/dL were observed which plateaued early. This study assessed changes in measured glomerular filtration
rate (mGFR) with tofacitinib relative to placebo in patients with active RA.
Methods: This was a randomised, placebo-controlled, Phase 1 study (NCT01484561). Patients were aged ≥18 years
with active RA. Patients were randomised 2:1 to oral tofacitinib 10 mg twice daily (BID) in Period 1 then placebo
BID in Period 2 (tofacitinib→ placebo); or oral placebo BID in both Periods (placebo→ placebo). Change in mGFR
was evaluated by iohexol serum clearance at four time points (run-in, pre-dose in Period 1, Period 1 end, and Period
2 end). The primary endpoint was the change in mGFR from baseline to Period 1 end. Secondary endpoints in-
cluded: change in mGFR at other time points; change in estimated GFR (eGFR; Cockcroft–Gault equation) and SCr;
efficacy; and safety.
Results: 148 patients were randomised to tofacitinib→ placebo (N = 97) or placebo→ placebo (N = 51). Baseline
characteristics were similar between groups. A reduction of 8% (90% confidence interval [CI]: 2%, 14%) from baseline in
adjusted geometric mean mGFR was observed during tofacitinib treatment in Period 1 vs placebo. During Period 2,
mean mGFR returned towards baseline during placebo treatment, and there was no difference between the two
treatment groups at the end of the study – ratio (tofacitinib→ placebo/placebo→ placebo) of adjusted geometric
mean fold change of mGFR was 1.04 (90% CI: 0.97, 1.11). Post-hoc analyses, focussed on mGFR variability in placebo→
placebo patients, were consistent with this conclusion. At study end, similar results were observed for eGFR and SCr.
Clinical efficacy and safety were consistent with prior studies.
Conclusion: Increases in mean SCr and decreases in eGFR in tofacitinib-treated patients with RA may occur in
parallel with decreases in mean mGFR; mGFR returned towards baseline after tofacitinib discontinuation, with no
significant difference vs placebo, even after post-hoc analyses. Safety monitoring will continue in ongoing and
future clinical studies and routine pharmacovigilance.
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Tofacitinib is an oral Janus kinase (JAK) inhibitor for the
treatment of rheumatoid arthritis (RA). In six phase-3
randomised controlled trials, tofacitinib 5 and 10 mg twice
daily (BID) as monotherapy or in combination with nonbio-
logic disease-modifying antirheumatic drugs (DMARDs)
were effective in reducing the signs and symptoms of RA,
improving physical function, patient-reported outcomes,
and structural preservation, and had a consistent safety pro-
file [1-6].
Tofacitinib treatment in pooled RA phase-3 studies
over 12 months resulted in mean increases from baseline
in serum creatinine (SCr) levels [7]. Increases occurred
predominantly within the first 3 months. Mean SCr in-
creases at month 3 were 0.07 and 0.08 mg/dL for tofaci-
tinib 5- and 10-mg BID doses, respectively, compared
with 0.04 mg/dL and 0.06 mg/dL in the placebo and
adalimumab groups, respectively [7]. Further analyses
suggested that effects on mean SCr plateaued, remained
within normal limits, were reversible and did not appear
to be associated with acute renal failure (ARF) or pro-
gressive worsening of renal function in the long-term ex-
tension (LTE) studies [7]. The mechanism behind these
SCr changes with tofacitinib treatment is unknown;
however, it may involve tofacitinib-induced changes in
inflammation and creatine kinase [7].
General toxicology preclinical investigations had dem-
onstrated that tofacitinib was not nephrotoxic in rats
and monkeys [8,9]. In a placebo-controlled, healthy vol-
unteer study, tofacitinib treatment (up to 15 mg BID for
14 days) had no effect on glomerular filtration rate
(GFR), effective renal plasma flow or creatinine clear-
ance [10]. Additionally, based upon a study of metfor-
min in healthy volunteers, tofacitinib does not appear to
interfere with tubular transport of creatinine [11,12].
Within the literature, it is important to recognise that
changes in SCr and measured GFR (mGFR) do not always
correlate [13-16]. As SCr is derived from muscle creatine,
many factors affect SCr independently of GFR and in-
clude, but are not limited to: age, gender, race, medica-
tions, diet, illness, muscle mass and muscle turnover
[13-16]. Patients with RA have reduced physical activity
and muscle mass, and present with various co-
morbidities, as well as increased inflammation [17-20].
Indeed, a prior analysis showed that the greater the
baseline C-reactive protein (CRP) and the greater the
change in CRP with tofacitinib treatment, the greater
the change in SCr [7]. Therefore, the interpretation of
SCr levels is complex in this population, and these fac-
tors need to be taken into consideration when estimat-
ing GFR in patients with RA.
While no effect of tofacitinib on mGFR was seen in
healthy volunteers, the interaction between inflamma-
tion and potential metabolic mechanisms influencingSCr suggests that measurement of GFR in patients with
RA is necessary to fully understand the impact of tofaci-
tinib on renal function. Therefore, the objectives of this
study were to determine whether tofacitinib induced
changes in mGFR relative to placebo in this population
of patients with active RA, and the extent to which these




Eligible participants were ≥18 years of age with a diagnosis
of RA based on the American College of Rheumatology
(ACR) 1987 Revised Criteria for Classification of RA [21].
Patients must have had an inadequate response to at least
one DMARD (non-biologic or biologic) due to lack of effi-
cacy or intolerance. Other key inclusion criteria included
active RA defined by ≥4 tender/painful joints and
≥4 swollen joints, and either erythrocyte sedimentation
rate (Westergren method) >28 mm/h or CRP >7 mg/L.
Patients were excluded if they had an estimated GFR
(eGFR) <40 mL/min (Cockcroft-Gault calculation).
Biologic DMARDs, potent immunosuppressive agents
(for example, cyclosporine, azathioprine), injectable gold,
penicillamine, intravenous (IV), intramuscular and intra-
articular corticosteroids were prohibited. The patient
was permitted (but was not required) to continue on
background non-biologic DMARDs.
Study design
This was a phase-1, randomised, placebo-controlled, parallel-
group, two-period study (A3921152; NCT01484561). The
study was conducted at 23 study centres (one in the Czech
Republic, Korea and Mexico; three in Germany; four in
Poland, Russia and Spain; five in the USA). There were
two study centres in Germany that received the study
drug, but did not randomise patients. Patients were rando-
mised 2:1 to one of two fixed sequences, each consisting
of two study periods: patients received oral tofacitinib
10 mg BID in period 1 and oral placebo BID in period 2
(tofacitinib→ placebo) or patients received oral placebo
BID in periods 1 and 2 (placebo→ placebo). Randomisa-
tion was achieved using an interactive voice response
system - an automated web/telephone randomisation
system containing the randomisation schedule. Protocol
amendments are listed in Additional file 1.
Data from phase-2 and phase-3 studies suggested a
greater increase in SCr with the tofacitinib 10-mg BID
dose versus the tofacitinib 5-mg BID dose; therefore, in
order to increase the probability of observing any poten-
tial effects on mGFR, the tofacitinib 10-mg BID dose
was selected for investigation in this study. From popu-
lation modelling analysis of the phase-2 study results,
steady-state SCr increases were predicted to be achieved
Kremer et al. Arthritis Research & Therapy  (2015) 17:95 Page 3 of 11in approximately 6 weeks in a typical patient with RA.
Therefore, the duration of tofacitinib treatment in this
study was chosen to be 6 weeks (through day 43 in
period 1). In a phase-2 study, modelling analysis pre-
dicted that after cessation of tofacitinib administration,
the 90% upper confidence limit of the mean increase in
SCr fell below 10% of pre-treatment baseline within 2 to
6 weeks. Therefore, to evaluate reversibility of the
increase in SCr in this study, renal function was to be
evaluated 4 weeks after the end of tofacitinib treatment
(day 29 in period 2). The selection of the tofacitinib
10-mg BID dose was based on the prior phase-2 and
phase-3 studies of tofacitinib in RA.
In period 1, patients received the study drug (tofacitinib
or placebo) in the evening of day 1 through to at least
the morning of day 43 (up to the morning of day 50).
Period 2 immediately followed the end of period 1. In
period 2, patients received placebo BID in the evening
of day 1 through to at least the morning of day 29 (up to
the morning of day 36). In period 1, the patient, the
investigator, the site staff and the sponsor were blinded
to individual patients’ treatment assignment. In period
2, only patients remained blinded. For the duration of
the study, the patients, investigator, the site staff and
sponsor remained blinded to the assigned treatment
sequence. The approximate total duration of treatment
with study drug (tofacitinib or placebo) in periods 1 and
2 was at least 10 weeks (up to 12 weeks). Patients
who completed at least period 1 through day 43 in this
study were given the option (if they were eligible for
enrollment) to enrol in an open-label LTE study
A3921024 (NCT00413699).
The study was conducted in compliance with the pro-
visions of the Declaration of Helsinki Good Clinical
Practice guidelines of the International Conference on
Harmonisation and relevant local country regulations.
All patients provided written informed consent. The
final protocol, amendments and consent documentation
were reviewed and approved by the Institutional Review
Board and/or Independent Ethics Committee at each
participating centre (Additional file 1).
Study endpoints and assessments
The study was exploratory in nature and was designed
with a primary objective of estimating the ratio (tofaciti-
nib→ placebo/placebo→ placebo) in the adjusted geo-
metric mean fold-change of mGFR from baseline to
period 1 end. Secondary endpoints included: change in
mGFR following tofacitinib withdrawal; changes in eGFR
(Cockcroft-Gault equation) and SCr with tofacitinib
treatment relative to placebo, and evaluation of the effi-
cacy and safety of tofacitinib in patients with active RA.
Each patient underwent mGFR evaluations by deter-
mining iohexol serum clearance at four pre-scheduledtime points: during the run-in period (between day 14
and day 2), pre-dose on day 1 of period 1, post-dose on
the last day of period 1 and post-dose on the last day of
period 2. Additionally, SCr levels were obtained at
screening, pre-dose on day 1 of period 1, and on the last
day of period 1 and of period 2. eGFR was calculated
(using the Cockcroft-Gault equation) at both screening
and pre-dose on day 1 of period 1 by the site, then at all
visits during treatment with the study drug by the spon-
sor. Iohexol serum clearance was determined after an IV
bolus injection of non-radioactive iohexol followed by
serial blood sampling. Further details on the iohexol
serum clearance procedure can be found in Additional
file 1.
Efficacy was assessed by ACR response rates of 20%,
50% and 70% (ACR20/50/70); disease activity score in
28 joints (DAS28)-3(CRP)/DAS28-4(CRP); and their
components. The incidence and severity of all adverse
events (AEs) were recorded; clinical laboratory tests,
vital signs and physical examinations were performed at
scheduled visits.
Statistical analyses
Details on sample size determination can be found in
Additional file 1. Statistical analyses focused on point
estimations and confidence intervals (CIs). No formal
hypothesis test was performed; P-values are considered
descriptive statistics. All analyses were performed on the
full analysis set (FAS) unless otherwise stated – defined as
all randomised patients who received ≥1 dose of study drug
(tofacitinib or placebo). Additionally, analysis of GFR data
was performed on the per-protocol analysis set (PPAS) -
defined as a subset of patients in the FAS, who completed
the treatment period and who had no major protocol devi-
ations that may impact renal function assessments.
mGFR was determined as iohexol serum clearance using
a non-linear mixed-effects modelling approach (NON-
MEM version 7.2) of the iohexol serum concentration-time
data. Serial blood sample collection was designed to
maximise precision of the estimate, assuming a two-
compartment model based on a prior study and literature
reports [10,22,23]. Iohexol clearance values were also
normalised by body surface area.
Baseline mGFR was calculated as the mean of the
values obtained in the run-in period and pre-dose on
day 1 of period 1. Following natural log transformation,
an analysis of covariance (ANCOVA) model was used to
analyse the mGFR change from baseline with treatment
and baseline mGFR (natural log-transformed) as covari-
ates. For change from period 1 end to period 2 end, the
ANCOVA model included treatment and the mGFR col-
lected at period 1 end (on log scale) as covariates. The
treatment difference and two-sided 90% CI on the log-
transformed scale were then back-transformed to derive
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Additional sensitivity analysis using a linear mixed-effects
model was performed with mGFR value (on log scale) as a
response variable, treatment group, visit and treatment
group by visit interaction as fixed effects and patients as
random effect. The eGFR and SCr data were analysed in a
similar manner.
To assess the robustness of our findings on the mGFR
changes, post-hoc ANCOVA was performed to exclude
patients who had an outlier mGFR result. An outlier
mGFR result was defined as the difference between
mGFR and eGFR falling outside the 95% limits of agree-
ment between the two methods of measurement. Distri-
bution of mGFR changes were graphically examined
using box and whisker plots.
For ACR variables, the normal approximation for the
difference in the binomial proportions was performed at
the end of each period. Response rate was calculated for
the data as is (no imputation) and using the last observa-
tion carried forward for skipped components and the
non-responder imputation after early withdrawals.
DAS28-3(CRP)/DAS28-4(CRP) was expressed as change
from baseline. The analysis was done using the ANCOVA
model including treatment and baseline as covariate. The
endpoint was also analysed by a linear mixed-effects
model with actual value as a response variable, treatment
group, visit and treatment group by visit interaction as
fixed effects and patients as random effect.Figure 1 Consolidated standards of reporting trials (CONSORT) diagram.Results
Patients
A total of 148 patients were randomised to treatment
(tofacitinib→ placebo, N = 97; placebo→ placebo, N = 51)
and received at least one dose of study medication. Of
these, 133 patients (89.9%) completed the study (tofaciti-
nib→ placebo, N = 88; placebo→ placebo, N = 45). All
148 patients were included in the FAS and were evaluated
for safety. Patient disposition is summarised in Figure 1.
The majority of patients were female (75.0%) and
white (93.9%), with a mean age of 50.3 years (range 22
to 77 years). RA disease duration ranged from 0.3 to
37 years. Patient demographics and baseline characteris-
tics are summarised in Table 1.
Renal endpoints
mGFR
Baseline mGFR was comparable between the two treat-
ment groups (Table 2). In the tofacitinib→ placebo group,
median mGFR decreased by 6.46 mL/min/1.73 m2 from
baseline to period 1 end (Table 2). Following tofacitinib
withdrawal in period 2, median mGFR increased by
1.68 mL/min/1.73 m2 compared with period 1. In the pla-
cebo→ placebo group, there was little change in mGFR at
period 1 end; however, at the end of period 2, median
mGFR decreased by 3.25 mL/min/1.73 m2 (Table 2).
Overall, at period 2 end compared with baseline, me-
dian mGFR decreased by 3.41 mL/min/1.73 m2 in the
Table 1 Summary of baseline demographics and disease characteristics (full analysis set)
Characteristic Tofacitinib→ placebo group Placebo→ placebo group
(N = 97) (N = 51)
Mean (SD) age, years 51.86 (12.68) 47.25 (11.84)
Sex, n (%)
Male 22 (22.7) 15 (29.4)
Female 75 (77.3) 36 (70.6)
Race, n (%)
White 90 (92.8) 49 (96.1)
Asian 3 (3.1) 1 (2.0)
Black 3 (3.1) 0
Other 1 (1.0) 1 (2.0)
Mean (SD) body mass index, kg/m2 28.71 (6.16) 28.11 (7.13)
Mean (SD) duration of rheumatoid arthritis 8.67 (7.49) 8.25 (7.94)
Prior corticosteroid use, n (%)
Yes 50 (51.5) 21 (41.2)
No 47 (48.5) 30 (58.8)
Prior DMARD use, n (%)
Yes 94 (96.9) 47 (92.2)
No 3 (3.1) 4 (7.8)
Prior NSAID use, n (%)
Yes 73 (75.3) 35 (68.6)
No 24 (24.7) 16 (31.4)
Prior methotrexate use, n (%)
Yes 87 (89.7) 47 (92.2)
No 10 (10.3) 4 (7.8)
Mean (SD) erythrocyte sedimentation rate, mm/h 45.34 (17.43) 47.08 (23.83)
Mean (SD) C-reactive protein, mg/L 18.37 (22.57) 15.66 (22.55)
Rheumatoid factor, n (%)
Positive 69 (71.1) 34 (66.7)
Negative 28 (28.9) 17 (33.3)
Mean (SD) DAS28-3(CRP) 5.27 (0.95) 5.31 (0.81)
Mean (SD) DAS28-4(CRP) 5.50 (1.05) 5.56 (0.93)
Mean (SD) Patient Assessment of Arthritis Pain 53.98 (22.77) 57.45 (21.04)
Mean (SD) Patient Global Assessment of Arthritis 56.13 (23.78) 58.67 (21.70)
Mean (SD) Physician Global Assessment of Arthritis 57.24 (17.83) 55.22 (17.11)
Mean (SD) tender/painful joint counts 20.41 (11.63) 23.43 (13.34)
Mean (SD) swollen joint counts 12.48 (6.76) 12.67 (6.91)
Mean (SD) HAQ-DI 1.49 (0.65) 1.41 (0.69)
DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ-DI, health assessment questionnaire-disability index; NSAID, non-steroidal
anti-inflammatory drug; SD, standard deviation.
Kremer et al. Arthritis Research & Therapy  (2015) 17:95 Page 5 of 11tofacitinib→ placebo group and by 3.88 mL/min/1.73 m2
in the placebo→ placebo group (Table 2).
Tofacitinib treatment in period 1 was associated with
a reduction of 8% (90% CI: 2%, 14%) from baseline in ad-
justed geometric mean mGFR versus placebo. The reduc-
tion in geometric mean mGFR associated with tofacitinibin period 1 reversed during placebo treatment in period 2,
and there was no statistically significant difference be-
tween the two treatment groups at the end of the study
(ratio 1.04; 90% CI: 0.97, 1.11). The geometric mean fold-
change in mGFR from baseline to the end of period 1 and
period 2 is shown in Figure 2A. The sensitivity analysis
Table 2 Descriptive statistics of change in mGFR, eGFR (Cockcroft-Gault) and serum creatinine (full analysis set)














Number 97 51 97 51 97 51
Mean (SD) 88.98 (18.79) 89.67 (21.33) 104.19 (28.42) 111.30 (26.91) 0.77 (0.15) 0.76 (0.17)
Median (Q1, Q3) 87.98 (75.76, 99.98) 86.99 (75.17, 98.20) 97.22 (82.43, 125.57) 107.22 (91.47, 134.89) 0.76 (0.67, 0.85) 0.75 (0.64, 0.84)
Change at end of period 1 from baseline
Number 91 46 92 46 92 46
Mean (SD) −6.73 (16.44) −0.50 (17.34) −3.59 (10.31) 1.28 (11.48) 0.03 (0.07) −0.00 (0.07)
Median (Q1, Q3) −6.46 (−11.85, 2.14) 0.82 (−5.48, 6.79) −3.36 (−9.18, 2.86) 2.30 (−5.71, 6.14) 0.02 (−0.02, 0.08) −0.01 (−0.05, 0.04)
Change at end of period 2 from baseline
Number 86 45 87 44 87 44
Mean (SD) −3.02 (17.55) −5.96 (20.66) 0.03 (10.15) 0.48 (9.54) 0.00 (0.07) −0.00 (0.05)
Median (Q1, Q3) −3.41 (−8.55, 3.65) −3.88 (−9.13, 7.58) −0.32 (−6.05, 5.74) 0.18 (−3.81, 4.28) 0.00 (−0.05, 0.05) 0.00 (−0.03, 0.03)
Change at end of period 2 from end of period 1
Number 86 45 87 44 87 44
Mean (SD) 2.92 (19.02) −5.41 (16.65) 3.71 (11.95) −0.97 (10.06) −0.03 (0.08) 0.00 (0.07)
Median (Q1, Q3) 1.68 (−3.60, 8.62) −3.25 (−12.24, 2.29) 2.94 (−4.45, 10.31) −2.07 (−7.29, 6.09) −0.02 (−0.07, 0.03) 0.01 (−0.04, 0.05)














Figure 2 Adjusted geometric mean fold-change from baseline
(90% CI) in measured glomerular filtration rate (mGFR) (A), estimated
GFR (eGFR) (B) and serum creatinine (SCr) (C) (full analysis set, analysis
of covariance, observed case).
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ANCOVA from the PPAS) were comparable with the
ANCOVA (FAS, observed case) analysis results.
Given the unexpected decline in mGFR in the placebo→
placebo group in period 2, as well as the observation of out-
liers (high or low mGFR values that did not appear to cor-
respond to SCr or eGFR for a given patient), a post-hoc
analysis was performed after excluding the outlier patients
(15 patients in the tofacitinib→ placebo group and 9 pa-
tients in the placebo→ placebo group). The results of the
post-hoc analysis were consistent with results for the pri-
mary analyses but the significant decline in mGFR in period2 for the placebo→ placebo group was no longer apparent
(geometric mean fold-change from baseline 0.98; 90% CI:
0.94, 1.01) (Table 3). A review of the outlier patients re-
vealed no consistent demographic factors or concomitant
medications, other than commonality of study centres.
To more fully understand the variability in mGFR changes
at the end of period 1 from baseline, an additional analysis
of patients with greatest changes from the mean (defined by
changes more than 1.5-times an interquartile distance from
the upper and lower quartiles from the box plots (Figure 3))
was undertaken. Similar proportions in each treatment
group fell into this category (six (6.6%) tofacitinib→ placebo
and three (6.5%) placebo→ placebo patients). Of these, four
tofacitinib→ placebo and two placebo→ placebo patients
had decreases from baseline (mean of run-in and pre-dose
day 1 mGFR measurements), and two tofacitinib→ placebo
patients and one placebo→ placebo patient had increases
from baseline in mGFR. In this analysis, mGFR measure-
ments at the end of period 1 were similar to one of the com-
ponents of the baseline for two patients. Additionally,
mGFR tended to revert to a value within the range of the
component baseline values at the end of period 2 for six pa-
tients. Increases in SCr were generally <0.06 mg/dL for this
group of patients (maximum SCr changes of 0.12 and
0.13 mg/dL for the tofacitinib→ placebo and placebo→ pla-
cebo groups, respectively). Discontinuations (one patient for
lack of efficacy and one patient for bronchopneumonia) oc-
curred at least 15 days into period 2.
eGFR (Cockcroft-Gault)
Baseline eGFR was comparable between the two treat-
ment groups (Table 2). In the tofacitinib→ placebo group,
median eGFR decreased from baseline to period 1 end
and then increased following tofacitinib withdrawal in
period 2 (Table 2). Overall, the median eGFR at period 2
end was similar compared with baseline (Table 2). In the
placebo→ placebo group, there was very little change in
median eGFR between the three time points (Table 2).
At period 1 end, there was a 5% (90% CI: 2%, 8%) reduc-
tion from baseline in geometric mean eGFR associated
with tofacitinib treatment versus placebo, which fully
reversed during period 2 (geometric mean fold-change
from end of period 1 to end of period 2, 1.03; 90% CI:
1.01, 1.05) and there was no difference between the two
treatment groups at period 2 end (ratio 0.99; 90% CI: 0.97,
1.02) (Figure 2B). Unlike the mGFR, there was no change
in the placebo→ placebo group in either period 1 (geo-
metric mean fold-change from baseline 1.01; 90% CI: 0.99,
1.04) or period 2 (geometric mean fold-change from end
of period 1 to end of period 2, 1.00; 90% CI: 0.97, 1.02).
Serum creatinine
Baseline SCr was comparable between the two treatment
groups (Table 2). At period 1 end there was a 5% (90%
Table 3 Post-hoc analysis of mGFR change by excluding patients who had an outlier mGFR result (ANCOVA)
mGFR (mL/min/1.73 m2)
Tofacitinib→ placebo group Placebo→ placebo group
Change at end of period 1 from baseline
Number 76 37
Adjusted geometric mean fold-change (90% CI) 0.91 (0.88, 0.93) 1.01 (0.97, 1.04)
Ratio of adjusted geometric mean fold-change (90% CI) 0.90 (0.86, 0.94)
Change at end of period 2 from baseline
Number 72 36
Adjusted geometric mean fold-change (90% CI) 0.96 (0.93, 0.99) 0.98 (0.94, 1.01)
Ratio of adjusted geometric mean fold-change (90% CI) 0.98 (0.94, 1.03)
Change at end of period 2 from end of period 1
Number 72 36
Adjusted geometric mean fold-change (90% CI) 1.06 (1.03, 1.09) 0.99 (0.95, 1.03)
Ratio of adjusted geometric mean fold-change (90% CI) 1.07 (1.02, 1.12)
Post-hoc analysis excluded those patients with a difference between mGFR and eGFR falling outside the 95% limits of agreement between the two methods of
measurement. ANCOVA, analysis of covariance; eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate.
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SCr associated with tofacitinib treatment versus placebo.
This SCr increase reversed during placebo treatment in
period 2, and at period 2 end the treatment ratio was
1.01 (90% CI: 0.98, 1.04) (Figure 2C). No change was ob-
served in SCr at the end of period 2 versus the end of
period 1 for the placebo→ placebo group.
Efficacy endpoints
Patients receiving tofacitinib reported significantly greater
improvements versus placebo in the efficacy endpoints
measured, namely, ACR20/50/70 response rates, and least
squares mean changes from baseline in DAS28-3(CRP)
and DAS28-4(CRP).
Safety
Treatment-emergent AEs (TEAEs) were reported in 42
and 26 patients in the tofacitinib→ placebo andFigure 3 Box and whisker plot of change in measured glomerular
filtration rate (mGFR) (full analysis set).placebo→ placebo groups, respectively. The majority of
AEs were mild or moderate in intensity. The most
frequently reported TEAEs were nasopharyngitis (n = 8
and n = 3), headache (n = 6 and n = 1), nausea (n = 5 and
n = 2) and urinary tract infection (n = 3 and n = 2) in the
tofacitinib→ placebo and placebo→ placebo groups,
respectively.
One tofacitinib→ placebo patient permanently discon-
tinued during the placebo treatment period due to a ser-
ious AE (SAE) of bronchopneumonia. Four placebo→
placebo patients experienced AEs resulting in permanent
discontinuation: increased SCr (Additional file 1), som-
nolence, lymphopaenia and urticaria. Seven and zero pa-
tients temporarily discontinued their study drug or
temporarily reduced their dose due to AEs in the tofaci-
tinib→ placebo and placebo→ placebo groups, respect-
ively; none of the AEs were serious. With the exception
of an AE of pharyngitis, all AEs leading to temporary
discontinuation or dose reduction occurred during
period 1.
Two SAEs (pelvic fracture and bronchopneumonia) out
of 97 patients occurred during period 2 in two tofaciti-
nib→ placebo patients. None of the 51 placebo→ placebo
patients had an SAE at any time. No patients experienced
an AE coded to the narrow standardised MedDRA (Med-
ical Dictionary for Regulatory Activities) query of ARF (in-
cluding preferred terms of acute phosphate nephropathy,
acute pre-renal failure, anuria, azotemia, continuous hae-
modiafiltration, dialysis, haemodialysis, nephropathy toxic,
oliguria, peritoneal dialysis, renal failure, renal impair-
ment). There were no deaths reported in this study.
No trends in clinically important treatment-related
changes in vital signs, electrocardiogram or laboratory
abnormalities were observed.
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The results of this study suggest that mean increases in
SCr and mean decreases in eGFR in patients with active
RA treated with tofacitinib 10 mg BID occur in parallel
with decreases in mGFR. Furthermore, these changes
were reversible following withdrawal of tofacitinib
10-mg BID treatment; although mean mGFR did not
return completely to baseline, there was no significant
difference between tofacitinib and placebo groups at the
end of the study. While this conclusion is complicated
by the unexpected observations in the placebo→ placebo
group in period 2, it is further supported by the post-hoc
analyses where the significant decline in the placebo→
placebo group during period 2 was no longer evident. The
mean changes in SCr and eGFR observed in this study are
similar to those reported in phase-2 and phase-3 RA stud-
ies of tofacitinib.
An unexpected finding was a decrease in mean and
median mGFR during the second period in placebo→
placebo patients; as no concomitant changes in SCr were
seen (the CIs for SCr changes were also much smaller
than for mGFR), the interpretation and significance of
the change in mGFR in the placebo→ placebo group
during this period remains unclear. Given the variability
in mGFR and not in SCr, as well as the lack of agree-
ment between the measurements for mGFR and SCr, it
is likely that these unexpected findings in mGFR reflect
measurement methodology issues rather than significant
changes in GFR. Several studies have shown iohexol
serum clearance to be highly correlated with the renal
clearance of inulin, the gold standard of GFR measure-
ment [22,24-27]; however, variability in mGFR measure-
ments is expected given the inherently technical and
complex nature of the iohexol serum clearance proced-
ure [16,28]. This study required frequent and numerous
timed blood samples to be collected and processed dur-
ing four separate study visits in which the iohexol pro-
cedure was performed. Additionally, the procedure was
conducted at multiple, global rheumatology study cen-
tres, rather than in a single clinical research unit, where
patient diet, hydration and exercise could not be as ri-
gidly controlled. Nonetheless, the variability observed in
this study was consistent with the assumed variability
used in the sample size calculation during protocol de-
velopment and was within the range from previously
published studies [10,29,30]. A decline in mGFR was
also observed in placebo subjects in an earlier study in-
vestigating the effect of tofacitinib on renal function in
healthy adult volunteers, hence, the importance of in-
cluding a placebo group in the current mGFR study
[10]. Post-hoc analyses were performed that excluded
any mGFR outliers – those patients with likely aberrant
mGFR results based on large discrepancies in mGFR
and eGFR measurements. In the outlier analyses, thedecline observed during period 2 for the primary ana-
lysis in the placebo→ placebo group was not observed;
however, the conclusions of the primary analyses that
there was no significant difference in mGFR between
tofacitinib and placebo groups at the end of the study
was preserved. Therefore, despite the variability and po-
tential technical limitations of the methodology, the
study still detected a mean change in mGFR in patients
with RA receiving tofacitinib.
Data on mGFR in patients with RA are limited. Changes
in SCr and mGFR were not seen in a study of healthy vol-
unteers dosed with tofacitinib, although study size and
duration differences may not allow statements of differen-
tial effects in a specific population [10]. This study was
not designed to address mechanisms for potential effects
of tofacitinib on SCr or mGFR nor the relative impacts of
inflammation and GFR changes on SCr; however, the re-
versibility of the effect, at least after short-term treatment,
is reassuring, and supports the results of the SCr analyses
across phase-2, phase-3 and LTE studies of tofacitinib in
patients with RA [7]. In those studies, the relationship to
baseline inflammation and its reduction, as well as to
serum creatine kinase, suggests additional mechanisms
may contribute to rises in SCr in patients receiving
tofacitinib.
When applying to clinical practice, the changes in SCr
and mGFR in tofacitinib-treated patients with RA should
also be considered in the context of the concomitant
medications received and the doses of such medications.
It is unlikely that such changes in mGFR and SCr of the
magnitude observed in this study will be clinically mean-
ingful in the vast majority of patients; however, clinical
judgement should be used when assessing changes in
SCr or mGFR in patients with RA receiving tofacitinib.
Data derived from a follow-up of patients on tofacitinib
for up to 5 years in an LTE study do not suggest
increased rates of renal AEs or progressive increases in
levels of SCr [31], but ongoing assessment will further
address long-term consequences.
Conclusions
In summary, despite some potential operational limita-
tions and technical challenges associated with the
measurement of mGFR, the results of this study suggest
that increases in SCr and decreases in eGFR in patients
with RA treated with tofacitinib may reflect decreases
in mGFR. Furthermore, changes in these parameters
with short-term tofacitinib treatment appear reversible
after discontinuation – mGFR returned towards baseline,
with no significant difference from placebo at the end of
the study, even after post-hoc analyses where the decline
in mGFR in placebo→ placebo patients was no longer
present. The mechanisms behind these changes in renal
endpoints are unknown. The overall safety and efficacy
Kremer et al. Arthritis Research & Therapy  (2015) 17:95 Page 10 of 11profiles were consistent with that of previous studies;
safety monitoring will continue in ongoing and future
clinical studies and routine pharmacovigilance to further
assess the long-term and real-world renal safety profile of
tofacitinib.
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